This compound is a pharmaceutical intermediate used in the manufacturing of alpha1-adrenergic blockers. It serves as a key intermediate for the production of medications such as alfuzosin, prazosin, terazosin, doxazosin, and IAAP, which are effective as antihypertensives.
Alcance del contenido: La información de esta página se refiere a la identificación química y a los contextos de suministro industrial, investigación y producción. No constituye una afirmación terapéutica, un consejo médico ni instrucciones de uso de medicamentos.
¿Adquiriendo o suministrando este compuesto?
Publique su inventario o una solicitud de compra
CAS 28888-44-0
Lifitegrast Impurity 125
Pharmaceutical impurity reference standard
N-(5-((Diphenylphosphoryl)methyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide
Pharmaceutical intermediate
Tert-Butyl 2-((4R,6S)-6-((E)-2-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate
Rosuvastatin calcium intermediate
N-nitroso-tamsulosin
pharmaceutical reference standard
8-bromoquinazoline-2,4(1H,3H)-dione
research compound
6-Bromo-2,4(1H,3H)-quinazolinedione
Pharmaceutical intermediate compound
8-Chloro-6-fluoroquinazoline-2,4-diol
Pharmaceutical intermediate for quinazoline derivatives
7-Bromo-8-fluoro-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione
Pharmaceutical intermediate
6,7-dimethoxy-1H-quinazoline-2,4-dione
KWNQIIMVPSMYEM-UHFFFAOYSA-N
COC1=C(C=C2C(=C1)C(=O)NC(=O)N2)OC